185 related articles for article (PubMed ID: 38495948)
1. Safety and Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes Mellitus Fasting during Ramadan: A Review.
Nakhleh A; Mazareeb J; Darawshi S; Masri A; Shehadeh N
Clin Med Insights Endocrinol Diabetes; 2024; 17():11795514241238058. PubMed ID: 38495948
[TBL] [Abstract][Full Text] [Related]
2. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes.
Abdelgadir E; Rashid F; Bashier A; Al Saeed M; Khalifa A; Alawadi F; Hassanein M
Diabetes Metab Syndr; 2019; 13(5):2927-2932. PubMed ID: 31425958
[TBL] [Abstract][Full Text] [Related]
3. Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes.
Bashier A; Khalifa AA; Abdelgadir EI; Al Saeed MA; Al Qaysi AA; Bayati MBA; Alemadi B; Bachet F; Alawadi F; Hassanein M
Oman Med J; 2018 Mar; 33(2):104-110. PubMed ID: 29657678
[TBL] [Abstract][Full Text] [Related]
4. A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting.
Rashid F; Abdelgadir E
Diabetes Metab Syndr; 2019; 13(2):1413-1429. PubMed ID: 31336501
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study.
Samkari MM; Bokhari NS; Alhajaji R; Ahmed ME; Al Raddadi A; Bahget AK; Saleh SF; Aljehani F; Alzahrani SH; Alsifyani SS; Samkari MM; Badr AF; Alalawi M; Al Sulaiman K
Saudi Pharm J; 2023 Jun; 31(6):972-978. PubMed ID: 37234349
[TBL] [Abstract][Full Text] [Related]
6. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh.
Pathan MDF; Akter N; Selim S; Saifuddin M; Qureshi NK; Kamrul-Hasan ABM; Hannan MA; Ahmed MAU; Mustari M; Chakraborty AK
Diabetes Metab Syndr Obes; 2022; 15():4011-4021. PubMed ID: 36578878
[TBL] [Abstract][Full Text] [Related]
8. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi.
Sheikh A; Das B; Sattar S; Islam N
Endocrine; 2023 Apr; 80(1):64-70. PubMed ID: 36580199
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors: A systematic review and meta-analysis.
Gad H; Al-Nassr N; Mohammed I; Khan A; MacDonald R; Mussleman P; Malik RA
J Diabetes Investig; 2022 May; 13(5):822-829. PubMed ID: 34953158
[TBL] [Abstract][Full Text] [Related]
11. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes.
Shao Y; Lim GJ; Chua CL; Wong YF; Yeoh ECK; Low SKM; Sum CF
Diabetes Res Clin Pract; 2018 Aug; 142():85-91. PubMed ID: 29802956
[TBL] [Abstract][Full Text] [Related]
12. Evolving physicians' perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting.
Beshyah SA; Hafidh K; Shaikh TG
Diabetes Res Clin Pract; 2020 Oct; 168():108389. PubMed ID: 32858101
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
Hassanein M; Echtay A; Hassoun A; Alarouj M; Afandi B; Poladian R; Bennakhi A; Nazar M; Bergmans P; Keim S; Hamilton G; Azar ST
Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28851109
[TBL] [Abstract][Full Text] [Related]
14. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
[TBL] [Abstract][Full Text] [Related]
15. Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
Lee SWH; Chen WS; Sellappans R; Md Sharif SB; Metzendorf MI; Lai NM
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013178. PubMed ID: 37435938
[TBL] [Abstract][Full Text] [Related]
16. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Patients with Type 2 Diabetes Mellitus during the Fasting Month of Ramadan.
Loh HH; Kamaruddin NA
Ann Acad Med Singap; 2020 Jul; 49(7):468-476. PubMed ID: 33000110
[TBL] [Abstract][Full Text] [Related]
18. Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia.
Goh KG; Zakaria MH; Raja Azwan RN; Bhajan Singh KK; Badrul Hisham MH; Hussein Z
Diabetes Metab Syndr; 2023 Jan; 17(1):102680. PubMed ID: 36473336
[TBL] [Abstract][Full Text] [Related]
19. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
20. Mitigation of hypoglycemia during Ramadan using the flash glucose monitoring system following dose adjustment of insulin and sulphonylurea in patients taking multiple glucose-lowering therapies (The PROFAST-IT Study).
Elhadd T; Bashir M; Baager KA; Ali HA; Almohannadi DHS; Dabbous Z; Malik RA; Abou-Samra AB;
Diabetes Res Clin Pract; 2021 Feb; 172():108589. PubMed ID: 33316309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
